Business Law Prof Blog
The Federal Option: Delaware as De Facto Agency, which takes a (sort of) different view. He argues that Delaware has become de facto federal agency, delegated by the federal government the power to make corporate law nationally, and that this system works well for now, though there might be circumstances where federal chartering – and the structural oversight that would come with it – might be appropriate. These could include situations where companies have received governmental bailouts, or where companies have committed significant wrongdoing and subject themselves to federal oversight as part of their settlement.
Of course, the concerns I’ve expressed in my posts are of a slightly different order – they’re about Delaware organizational law extending beyond the boundaries of internal affairs (and Delaware’s ability to define those boundaries in the first place) – but still, it’s an interesting holistic look at Delaware’s role in the co
Share this article
Share this article
ResearchAndMarkets.com s offering.
This report provides an analysis of the RCS market including drivers, technical issues, forecasts and future outlook. It is a must-read for any organization focused on monetizing voice over LTE and 5G, data and messaging services, and integrating third-party value-added apps and content with carriers for next-generation consumer and enterprise solutions.
The report analyzes RCS technologies and capabilities for use in applications by legacy carriers as well as OTT players, enterprise, and other third parties. The report also evaluates vendor strategies and initiatives including plans for new RCS based solutions.
The report also assesses the RCS market outlook for communication service providers as well as opportunities for enterprise organizations to leverage RCS capabilities such as the combination of rich calls, messaging, and videos as well as branded communications. The report includes analysis and fore
Legal Profession Blog
The Delaware Supreme Court affirmed the denial of relief based on an alleged undisclosed judicial conflict
In 2010, Appellants Meso Scale Diagnostics, LLC and Meso Scale Technologies, LLC (collectively “Meso”) filed suit in the Court of Chancery against Appellee entities Roche Diagnostics GmbH, Roche Diagnostics Corp., Roche Holding Ltd., IGEN LS LLC, Lilli Acquisition Corp., IGEN International, Inc., and Bioveris Corp. (collectively “Roche”), all of which are or were affiliates or subsidiaries of the F. Hoffmann La Roche, Ltd. family of pharmaceutical and diagnostics companies. Meso alleged two counts of breach of contract. Roche prevailed at trial, and this Court affirmed the judgment in 2014.